Journal profile · Oncology
Targeted Oncology
ISSN 1776-2596 · eISSN 1776-260X · Springer International Publishing · FRANCE · Quarterly · Founded 2006
Targeted Oncology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.97; hybrid open access; APC about USD 4,990; median 100 days to acceptance (53 articles, last 24 months); community-reported acceptance: fairly easy; 71 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Targeted Oncology is published by Springer International Publishing and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers and Colorectal Cancer Treatments and Studies, together about 29.9% of its articles. Its main subfields are Pulmonary and Respiratory Medicine and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes: Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches. Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways. Current Opinion articles that place interesting areas in perspective. Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations. Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement. Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Martin ChopraPublisher website
Editorial board by country: none in mainland China; most named United States 15, Japan 4, Germany 3, France 3, Australia 3 (36 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine13.3%
- Cancer Immunotherapy and BiomarkersMedicine8.3%
- Colorectal Cancer Treatments and StudiesMedicine8.3%
- Lung Cancer Research StudiesMedicine6.7%
- HER2/EGFR in Cancer ResearchMedicine6.6%
- Renal cell carcinoma treatmentMedicine5.5%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology4.6%
- Lung Cancer Diagnosis and TreatmentMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbasePublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.97LetPub ·
- Impact factor (publisher) 2025
- 5.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 5Publisher website ·
- CiteScore 2026-06
- 6.9LetPub ·
- SJR 2026-06
- 1.44LetPub ·
- SNIP 2026-06
- 1.15LetPub ·
- h-index
- 35LetPub ·
- h-index
- 73OpenAlex ·
- i10-index
- 683OpenAlex ·
- 2-year mean citedness
- 4.86OpenAlex ·
- Self-citation rate
- 3.9%LetPub ·
- Share of gold OA articles
- 50.46%LetPub ·
Volume
- Articles per year
- 63LetPub ·
- Downloads per year (publisher) 2025
- 540,900Publisher website ·
Articles by year OpenAlex count · 1,237 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 58 | 45 | 34 |
| 2025 | 71 | 45 | 333 |
| 2024 | 96 | 59 | 727 |
| 2023 | 82 | 55 | 1,112 |
| 2022 | 75 | 48 | 834 |
| 2021 | 76 | 49 | 2,289 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
100 daysMedian, submission to acceptance · P25–P75 65 days – 134 days
- Acceptance to online
- median 21 days (93 articles)
- Submission to online
- median 121 days
- Sample
- 53 articles with submission and acceptance dates (153 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 5 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,990 / EUR 3,890 / GBP 3,090 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Page charges
- Charged; see the journal's website for the amount
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Abstract
- 150–250 words
Article types accepted10
- editorialInternal Review by Editorial Staff: The journal editor will perform an initial appraisal of each manuscript. If your paper has been peer reviewed by another jou…Length not stated
- meta-analysisThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- opinionThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- original researchThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- original research articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- perspectiveThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- protocolThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- reviewThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- review articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- systematic reviewThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship Principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- License & copyright Copyright and license term – CC BY-NC
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution-NonCommercial 4.0 International License Find more about the license agreement Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Targeted Oncology, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer International Publishing
- Country or region
- FRANCE
- Language
- English
- Frequency
- Quarterly
- Founded
- 2006
- ISSN
- 1776-2596
- Electronic ISSN
- 1776-260X
- Latest issue on the website
- Volume 21, Issue 4 (July 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Targeted Oncology
What CAS zone is Targeted Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Targeted Oncology is in Zone 3 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Targeted Oncology?
The latest impact factor listed by LetPub is 4.97; CiteScore 6.9, h-index 73.
How long does peer review take at Targeted Oncology?
Based on the dates recorded on 53 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 100 days (interquartile range 65–134 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Targeted Oncology based?
Of the 36 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (15), Japan (4) and Germany (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Targeted Oncology?
According to LetPub and DOAJ records, Targeted Oncology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE and Embase; that list has not been checked against each database.
Is Targeted Oncology open access, and what is the APC?
Targeted Oncology is a hybrid journal. For open-access publication: APC about USD 4,990.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .